MedTrace Logo

Statin Combined with Amlodipine Treats Primary Aldosteronism

NCT06523465 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2024-11-22

No results posted yet for this study

Summary

The drug treatment for primary aldosteronism (PA) is limited and difficult to improve long-term cardiovascular outcomes. This study plans to enroll patients with primary aldosteronism and randomly divide into 3 groups: scheme 1: Statin combined with amlodipine besylate, scheme 2: Statin combined with Spironolactone and Amlodipine besylate. scheme 3: Amlodipine besylate combined with Spironolactone , to observe the changes in plasma aldosterone level, 24-hour urinary aldosterone, blood pressure, and long-term cardiovascular risk.

Conditions

  • Primary Aldosteronism
  • Statin
  • Mineralocorticoid Receptor Antagonist
  • Hypertension

Interventions

DRUG

Simvastatin combined with Amlodipine besylate

6-month treatment of Simvastatin combined with Amlodipine besylate

DRUG

Simvastatin combined with Spironolactone and Amlodipine besylate.

6-month treatment of Simvastatin combined with Spironolactone and Amlodipine besylate.

DRUG

Amlodipine besylate combined Spironolactone

6-month treatment of Amlodipine besylate combined with Spironolactone

Sponsors & Collaborators

  • Third Military Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-10
Primary Completion
2025-12-30
Completion
2026-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06523465 on ClinicalTrials.gov